Search Results - "Burstein, Aaron H."

Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis.

Authors: Burstein, Aaron H. Brantley, Scott J. Dunn, Imogene et al.

Source: Clinical Pharmacology in Drug Development. May2019, Vol. 8 Issue 4, p426-435. 10p.

Effect of TTP488 in patients with mild to moderate Alzheimer's disease.

Authors: Burstein, Aaron H. Grimes, Imogene Galasko, Douglas R. et al.

Source: BMC Neurology. 2014, Vol. 14 Issue 1, p1-17. 17p. 4 Charts, 3 Graphs.

The impact of lecanemab and donanemab on future Alzheimer's disease clinical development.

Authors: Dickson, Samuel P. Mallinckrodt, Craig Burstein, Aaron H et al.

Source: Alzheimer's & dementia: the journal of the Alzheimer's Association Dec2024 Supplement; Vol. 20 (S6).

Journal Info: Publisher: Wiley-Blackwell ISSN: 1552-5260

O4‐11‐04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES.

Authors: Valcarce, Carmen Dunn, Imogene Burstein, Aaron H.

Source: Alzheimer's & dementia: the journal of the Alzheimer's Association Jul2019 7S Part 24; Vol. 15.

Journal Info: Publisher: Wiley-Blackwell ISSN: 1552-5260